Randomized Phase II Trial of VK2809, an Investigational Thyroid Hormone Receptor Agonist, vs Placebo in NAFLD With Hyperlipidemia

April 10-14, 2019; Vienna, Austria
Patients treated with VK2809 for 12 weeks showed significantly reduced LDL-C and liver fat content vs those treated with placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 179 KB
Released: April 22, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
AbbVie
Gilead Sciences

Related Content

Hear CCO faculty Philip Newsome discuss the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Philip N. Newsome, PhD, FRCPE Released: February 12, 2020

CCO faculty Dr Juan Frias discusses the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Juan Pablo Frias, MD, FACE Released: February 5, 2020

Juan Frias and Philip Newsome: Learn about the agents in phase II and III clinical trials and their potential use in treatment.

Juan Pablo Frias, MD, FACE Philip N. Newsome, PhD, FRCPE Released: January 28, 2020

Hear CCO faculty Rita Basu, MD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests

Rita Basu, MD Released: January 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue